METHYLDOPA 250 MG
METHYLDOPA : 250 MG · DIN 00360260 · AA PHARMA INC
Health Canada status: MARKETED
What is METHYLDOPA?
METHYLDOPA 250 MG contains METHYLDOPA : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 00360260, held by AA PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 04-Apr-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00360260 |
|---|---|
| Brand name | METHYLDOPA |
| Generic / active ingredient | METHYLDOPA : 250 MG |
| Manufacturer | AA PHARMA INC |
| Strength | 250 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C02AB02 METHYLDOPA (RACEMIC) |
| AHFS class | 24:08.16 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 04-Apr-2011 |
| Original market date | 1976-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code C02AB02 METHYLDOPA (RACEMIC). 3 of 20 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| METHYLDOPA | 125 MG | TABLET | AA PHARMA INC | MARKETED | DIN 00360252 |
| METHYLDOPA | 500 MG | TABLET | AA PHARMA INC | MARKETED | DIN 00426830 |
| ALDOMET ESTER HCL INJ | 250 MG / 5 ML | LIQUID | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | DIN 00016187 |
| ALDOMET TAB 125MG | 125 MG | TABLET | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | DIN 00016551 |
| ALDOMET TAB 250MG | 250 MG | TABLET | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | DIN 00016578 |
| ALDOMET TAB 500MG | 500 MG | TABLET | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | DIN 00016586 |
| DOPAMET TAB 125MG | 125 MG | TABLET | ICN CANADA LTD. | CANCELLED POST MARKET | DIN 00353620 |
| DOPAMET TAB 250MG | 250 MG | TABLET | ICN CANADA LTD. | CANCELLED POST MARKET | DIN 00250392 |
| DOPAMET TAB 500MG | 500 MG | TABLET | ICN CANADA LTD. | CANCELLED POST MARKET | DIN 00353639 |
| MEDIMET 250TAB | 250 MG | TABLET | MEDIC LABORATORY LTÉE | CANCELLED POST MARKET | DIN 00385077 |
Who else supplies METHYLDOPA (RACEMIC) worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. METHYLDOPA (RACEMIC) appears in 7 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.